Publications by authors named "James Ferrara"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

414

Total Likes

229

Extended Reach

927,767

Social Features

91
T
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.
Yu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, Ioannis E Louloudis, Paibel Aguayo-Hiraldo, James L M Ferrara

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD.
Aaron Etra, James L M Ferrara, John E Levine

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.
Yu Akahoshi, Yoshihiro Inamoto, Nikolaos Spyrou, Hideki Nakasone, Marcio A Diniz, James L M Ferrara

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.
Ioannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, Amin Alousi, Nikolaos Katsivelos, James L M Ferrara

Transplant Cell Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk, James L M Ferrara

Transplant Cell Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-FLT PET and Blood-based Biomarkers for Identifying Gastrointestinal Graft versus Host Disease after Allogeneic Cell Transplantation.
Jennifer Holter-Chakrabarty, Lacey McNally, John Levine, James Ferrara, Sara K Vesely

Radiol Imaging Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.
Carlos A Ortega Rios, Muna Qayed, Aaron M Etra, Ran Reshef, Richard Newcomb, James L M Ferrara

Transplant Cell Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.
Yu Akahoshi, Nikolaos Spyrou, Daniela Weber, Paibel Aguayo-Hiraldo, Francis Ayuk, James L M Ferrara

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.
Zachariah DeFilipp, Haesook T Kim, Nikolaos Spyrou, Nikolaos Katsivelos, Steven Kowalyk, James L M Ferrara

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Muna Qayed, Urvi Kapoor, Scott Gillespie, Adrianna Westbrook, Paibel Aguayo-Hiraldo, James L M Ferrara

Transplant Cell Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.
Aaron Etra, Najla El Jurdi, Nikolaos Katsivelos, Deukwoo Kwon, Stephanie Gergoudis, James L M Ferrara

Blood Adv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The reparative immunologic consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
Daniela Guisado, Sayali Talware, Xiaoli Wang, Andrew Davis, Elbek Fozilov, James L M Ferrara

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Day 14 Endpoint for Acute GVHD Clinical Trials.
Nikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, George Morales, Rahnuma Beheshti, James L M Ferrara

Transplant Cell Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Yu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, Paibel Aguayo-Hiraldo, Francis Ayuk, James L M Ferrara

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects.
Mariano Prado-Acosta, Seihwan Jeong, Alberto Utrero-Rico, Tatiana Goncharov, Joshua D Webster, James L M Ferrara

Sci Transl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The utility of biomarkers in acute GVHD prognostication.
Nikolaos Spyrou, Yu Akahoshi, Francis Ayuk, Ernst Holler, Hannah Choe, James L M Ferrara

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Monzr M Al Malki, Kaitlyn London, Janna Baez, Yu Akahoshi, William J Hogan, James L M Ferrara

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.
Yu Akahoshi, Nikolaos Spyrou, William J Hogan, Francis Ayuk, Zachariah DeFilipp, James L M Ferrara

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use.
Daniela Weber, Markus Weber, Elisabeth Meedt, Sakhila Ghimire, Daniel Wolff, James L M Ferrara

Blood Adv· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
Aaron Etra, Alexandra Capellini, Amin Alousi, Monzr M Al Malki, Hannah Choe, James L M Ferrara

Blood· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute GVHD: New approaches to clinical trial monitoring.
Nikolaos Spyrou, John E Levine, James L M Ferrara

Best Pract Res Clin Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mannan-Binding Lectin Promotes Murine Graft-versus-Host Disease by Amplifying Lipopolysaccharide-Initiated Inflammation.
David Heja, Dongchang Zhao, Evan Cody, Arun Cumpelik, Pik Chin Lim, James Ferrara

Transplant Cell Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification.
Aaron Etra, Stephanie Gergoudis, George Morales, Nikolaos Spyrou, Jay Shah, James L M Ferrara

Blood Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-host disease: establishing IL-33 as an important costimulatory molecule.
James Ferrara, Mariano Prado-Acosta

J Clin Invest· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis